Daehan Nupharm Co.,Ltd. (KOSDAQ:054670)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,010.00
+20.00 (0.29%)
At close: Apr 25, 2025, 3:30 PM KST

Daehan Nupharm Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2012 FY 2011 FY 2010 FY 2009 FY 2008 2005 - 2007
Period Ending
Apr '25 Dec '12 Dec '11 Dec '10 Dec '09 Dec '08 2005 - 2007
Market Capitalization
97,54569,21385,861112,471123,80759,360
Upgrade
Market Cap Growth
12.90%-19.39%-23.66%-9.16%108.57%-63.45%
Upgrade
Enterprise Value
-113,126127,357145,501147,52189,584
Upgrade
Last Close Price
6950.005039.866252.108189.778800.664395.56
Upgrade
PE Ratio
--133.42-343.2410.33
Upgrade
PS Ratio
1.791.441.932.273.061.75
Upgrade
PB Ratio
1.321.021.161.531.620.77
Upgrade
P/TBV Ratio
1.371.071.231.541.630.77
Upgrade
P/FCF Ratio
--38.80--14.73
Upgrade
P/OCF Ratio
56.08269.5025.12--13.98
Upgrade
EV/Sales Ratio
-2.362.862.933.652.64
Upgrade
EV/EBITDA Ratio
-23.2720.7828.1131.46158.55
Upgrade
EV/EBIT Ratio
-32.7823.7731.8834.781490.40
Upgrade
EV/FCF Ratio
--57.56--22.23
Upgrade
Debt / Equity Ratio
0.590.700.540.480.320.40
Upgrade
Debt / EBITDA Ratio
7.359.856.466.785.2655.03
Upgrade
Debt / FCF Ratio
--17.91--7.72
Upgrade
Asset Turnover
0.420.380.360.430.350.29
Upgrade
Inventory Turnover
3.343.883.553.862.782.54
Upgrade
Quick Ratio
0.971.031.091.101.460.81
Upgrade
Current Ratio
1.151.201.271.421.881.12
Upgrade
Return on Equity (ROE)
-5.45%-7.79%0.87%-3.70%2.11%7.94%
Upgrade
Return on Assets (ROA)
2.09%1.70%2.73%2.47%2.30%0.03%
Upgrade
Return on Capital (ROIC)
2.30%1.88%3.02%2.72%2.54%0.03%
Upgrade
Return on Capital Employed (ROCE)
5.40%4.30%6.50%5.60%4.90%0.10%
Upgrade
Earnings Yield
-4.11%-7.99%0.75%-2.46%0.29%9.68%
Upgrade
FCF Yield
-0.78%-1.42%2.58%-10.04%-3.47%6.79%
Upgrade
Dividend Yield
1.43%-----
Upgrade
Buyback Yield / Dilution
-6.45%0.24%2.36%0.07%-3.67%-20.86%
Upgrade
Total Shareholder Return
-4.99%0.24%2.36%0.07%-3.67%-20.86%
Upgrade
Updated Nov 13, 2013. Source: S&P Global Market Intelligence. Standard template. Financial Sources.